Early Donor Chimerism Levels Predict Relapse and Survival after Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning
Ran Reshef(Abramson Cancer Center), David Porter(University of Pennsylvania), Kathryn A. Lafferty(University of Pennsylvania), Pavel Vassilev(University of Pennsylvania), Edward A. Stadtmauer(University of Pennsylvania), Saar Gill(Parker Institute for Cancer Immunotherapy), Jacqueline Smith(Roslin Institute), Selina M. Luger(University of Pennsylvania), Alison W. Loren(University of Pennsylvania), Rosemarie Mick(University of Pennsylvania), Noelle V. Frey(Hospital of the University of Pennsylvania), Elizabeth O. Hexner(University of Pennsylvania), Vivianna M. Van Deerlin(Hospital of the University of Pennsylvania), James K. Mangan(UC San Diego Health System)
Cited by 67
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k